Trial Condition(s):

Age-related macular degeneration (AMD), Central retinal vein occlusion (CRVO), Diabetic Macular Edema (DME)

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Bayer Identifier:

18498

ClinicalTrials.gov Identifier:

NCT02585401

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Inclusion Criteria
This study will be conducted with retinal specialists and ophthalmologists in Canada who have prescribed and/or administered aflibercept to at least 1 patient in the past 6 months.
Exclusion Criteria
-  None applied

Trial Summary

Enrollment Goal
99
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Canada

Status
Completed
 

Trial Design